BACKGROUND: Endometrial cancer (EC) is a common malignancy worldwide. It is often preceded by endometrial hyperplasia, whose management and risk of neoplastic progression vary. Previously, the authors have shown that the tetraspan protein epithelial membrane protein-2 (EMP2) is a prognostic indicator for EC aggressiveness and survival. Here the authors validate the expression of EMP2 in EC, and further examine whether EMP2 expression within preneoplastic lesions is an early prognostic biomarker for EC development. METHODS: A tissue microarray (TMA) was constructed with a wide representation of benign and malignant endometrial samples. The TMA contains a metachronous cohort of cases from individuals who either developed or did not develop EC. Intensity and frequency of EMP2 expression were assessed using immunohistochemistry. RESULTS: There was a stepwise, statistically significant increase in the average EMP2 expression from benign to hyperplasia to atypia to EC. Furthermore, detailed analysis of EMP2 expression in potentially premalignant cases demonstrated that EMP2 positivity was a strong predictor for EC development. CONCLUSIONS: EMP2 is an early predictor of EC development in preneoplastic lesions. In addition, combined with our previous findings, these results validate EMP2 as a novel biomarker for EC development.
BACKGROUND:Endometrial cancer (EC) is a common malignancy worldwide. It is often preceded by endometrial hyperplasia, whose management and risk of neoplastic progression vary. Previously, the authors have shown that the tetraspan protein epithelial membrane protein-2 (EMP2) is a prognostic indicator for EC aggressiveness and survival. Here the authors validate the expression of EMP2 in EC, and further examine whether EMP2 expression within preneoplastic lesions is an early prognostic biomarker for EC development. METHODS: A tissue microarray (TMA) was constructed with a wide representation of benign and malignant endometrial samples. The TMA contains a metachronous cohort of cases from individuals who either developed or did not develop EC. Intensity and frequency of EMP2 expression were assessed using immunohistochemistry. RESULTS: There was a stepwise, statistically significant increase in the average EMP2 expression from benign to hyperplasia to atypia to EC. Furthermore, detailed analysis of EMP2 expression in potentially premalignant cases demonstrated that EMP2 positivity was a strong predictor for EC development. CONCLUSIONS:EMP2 is an early predictor of EC development in preneoplastic lesions. In addition, combined with our previous findings, these results validate EMP2 as a novel biomarker for EC development.
Authors: W T Creasman; F Odicino; P Maisonneuve; U Beller; J L Benedet; A P Heintz; H Y Ngan; M Sideri; S Pecorelli Journal: J Epidemiol Biostat Date: 2001
Authors: Stephen J Freedland; David B Seligson; Alvin Y Liu; Allan J Pantuck; Sun H Paik; Steve Horvath; Jeffrey A Wieder; Amnon Zisman; David Nguyen; Cho-Lea Tso; Aarno V Palotie; Arie S Belldegrun Journal: Prostate Date: 2003-04-01 Impact factor: 4.104
Authors: Kunal S Patel; Sameer Kejriwal; Michel M Sun; Samasuk Thammachantha; Courtney Duong; Ann Chan; Nina Cherian; Prasanth Romiyo; Lynn K Gordon; William Yong; Madhuri Wadehra; Isaac Yang Journal: J Neurooncol Date: 2020-01-24 Impact factor: 4.130
Authors: Maoyong Fu; Erin L Maresh; Gustavo F Helguera; Meagan Kiyohara; Yu Qin; Negin Ashki; Tracy R Daniels-Wells; Najib Aziz; Lynn K Gordon; Jonathan Braun; Yahya Elshimali; Robert A Soslow; Manuel L Penichet; Lee Goodglick; Madhuri Wadehra Journal: Mol Cancer Ther Date: 2014-01-21 Impact factor: 6.261
Authors: Peggy S Sullivan; Erin L Maresh; David B Seligson; Omar Habeeb; Madhuri Wadehra; Lee Goodglick; Oliver Dorigo Journal: Mod Pathol Date: 2012-03-30 Impact factor: 7.842
Authors: Lawrance K Chung; Panayiotis E Pelargos; Ann M Chan; Joanna V Demos; Carlito Lagman; John P Sheppard; Thien Nguyen; Yu-Ling Chang; Seyed A Hojat; Robert M Prins; Linda M Liau; Leia Nghiemphu; Albert Lai; Timothy F Cloughesy; William H Yong; Lynn K Gordon; Madhuri Wadehra; Isaac Yang Journal: Brain Tumor Pathol Date: 2017-09-08 Impact factor: 3.298
Authors: Maoyong Fu; Sarah Brewer; Tove Olafsen; Anna M Wu; Lynn K Gordon; Jonathan Said; Jonathan Braun; Madhuri Wadehra Journal: Mol Imaging Biol Date: 2013-02 Impact factor: 3.488